Abstract:OBJECTIVE:To investigate the apoptosis and Fas (CD95) expression of T lymphocytes from the peripheral blood and peritoneal fluid of the patients with ovarian cancer and their relationship with CA125. METHODS:Apoptosis and Fas expression of peritoneal fluid and peripheral blood T lymphocytes were assessed by flow cytometry. Peripheral blood samples were obtained from the following objects respectively: patients with stage III - IV ovarian cancer (n = 18) before and after treatment, patients with stage I - II ovarian cancer (n = 15), patients with benign ovarian tumor (n = 18), patients with Krukenberg tumor (n = 6) and normal control (n = 20). Peritoneal fluids were obtained from all the patients with ovarian cancer, Krukenberg tumor and ten patients with benign ovarian tumor. Level of serum CA125 of the patients with ovarian cancer was assessed. RESULTS:In the patients with stage III - IV ovarian cancer, the apoptosis level of the peripheral blood T lymphocytes was 5.55 (3.57 - 9.62)%, significantly higher than those from the patients with stage I - II ovarian cancer, patients with benign ovarian tumor, controls (P < 0.008 in all instances) and the patients with stage III - IV ovarian cancer after treatment (P < 0.05). The intensity of Fas expression of the peripheral blood T lymphocytes from the patients with stage III - IV ovarian cancer was 51 +/- 10, significantly higher than that from controls (P < 0.05). In peritoneal fluid, the apoptosis rates of T lymphocytes, positive rate and intensity of Fas expression on T lymphocytes from patients with stage I - II and stage III - IV ovarian cancer were 17.41 (7.06 - 24.56)%, (57 +/- 16)%, (55 +/- 11)% and 34.06 (17.03 - 44.65)%, (66 +/- 12)%, (70 +/- 24)%, respectively, increased significantly compared with those from patients with benign ovarian tumor, which were 0.78 (0.67 - 1.44)%, (37 +/- 6)%, 43 +/- 6, respectively (P < 0.01 in all instances). The apoptosis level and positive rate of Fas expression on peritoneal fluid T lymphocytes from patients with stage III - IV ovarian cancer were significantly higher than those from patients with Krukenberg tumor (P < 0.01). There was a positive correlation between the serum CA125 level and the apoptosis level of peritoneal fluid T cell in the patients with stage I - II ovarian cancer (r = 0.77, P = 0.009). For ovarian cancer, the apoptosis level of peritoneal fluid T lymphocytes from patients with the serum CA125 > 500 KU/L was higher than that from the patients with the serum CA125 < or = 500 KU/L (P = 0.009). CONCLUSIONS:(1) Extraordinarily increased apoptosis of T cells may play an important role in the development of systemic and celiac immunodeficiency in the patients with ovarian cancer. In contrast with the patients with Krukenberg tumor, the patients with advanced ovarian cancer hare higher percentage of apoptotic peritoneal fluid T lymphocytes, which shows the particularity of local immunity defect. (2) For the patients with ovarian cancer, efficient treatment can decrease the percentage of apoptotic peripheral blood T lymphocytes. (3) The increased positive rate and intensity of Fas expression on peritoneal fluid T lymphocytes stressed the significance of Fas interference in the treatment of ovarian cancer. (4) Level of serum CA125 can reflect the celiac immunity defection in patients with ovarian cancer.

[The Clinical Value of Tissue Polypeptide Antigen in Ovarian Carcinoma].

Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies

[Clinical study of serum tissue polypeptide-specific antigen in breast cancer].

The Clinical Value of Serum CA125, HE4 and OPN in the Diagnosis of Ovarian Cancer

Combined evaluation of some tumor associated antigens in the monitoring of integrated surgical and chemotherapeutic treatment of epithelial ovarian cancer

Evaluation of Serum CA125-Tn Glycoform in Peritoneal Dissemination and Surgical Completeness of High-Grade Serous Ovarian Cancer

Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers

Diagnostic value of tissue polypeptide specific antigen in serum for patients with pancreatic carcinoma

Clinical Value of CA125, CA19-9, CEA, CA72-4, and TPA in Borderline Ovarian Tumor

[Significance of tumor markers in the treatment of patients with ovarian malignancies]

Diagnostic Value of Total Prostate Specifc Antigen (TPSA) in Women with Breast Cancer in the Molecular Subtyping Era.

Association of Tumor Markers with Total Testosterone in the Serum of Women with Polycystic Ovary Syndrome

Diagnostic Value of Serum TPA in 11 Types of Malignant Tumors

Predictive value of thrombomodulin and endothelial cell protein C receptor levels in patients with ovarian cancer

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors

TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer

The values of the expression of CA125 in serum, ascites and tissue in patients with ovarian cancer

[Value of Serum CA(125) Detection for Predicting Recurrence and Prognosis in Ovarian Epithelial Cancer].

Diagnostic Values in Ovarian Cancer with the Measurement of Serum Human Epididymis Secretory Protein 4 Combined with CA125 and Osteopontin

Study of Apoptosis and Fas Expression of Peritoneal Fluid and Peripheral Blood T Lymphocytes in Patients with Epithelial Ovarian Cancer and Their Relationship with CA125

Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value As a Biomarker